Heparin induces α-synuclein to form new fibril polymorphs with attenuated neuropathology

Youqi Tao1,2,10, Yunpeng Sun3,4,10, Shiran Lv3,4, Wencheng Xia3,4, Kun Zhao3,4, Qianhui Xu3,4, Qinyue Zhao1,2, Lin He1, Weidong Le5, Yong Wang6,7, Cong Liu3,4 & Dan Li1,8,9

α-Synuclein (α-syn), as a primary pathogenic protein in Parkinson’s disease (PD) and other synucleinopathies, exhibits a high potential to form polymorphic fibrils. Chemical ligands have been found to involve in the assembly of α-syn fibrils in patients’ brains. However, how ligands influence the fibril polymorphism remains vague. Here, we report the near-atomic structures of α-syn fibrils in complex with heparin, a representative glycosaminoglycan (GAG), determined by cryo-electron microscopy (cryo-EM). The structures demonstrate that the presence of heparin completely alters the fibril assembly via rearranging the charge interactions of α-syn both at the intramolecular and the inter-protofibrillar levels, which leads to the generation of four fibril polymorphs. Remarkably, in one of the fibril polymorphs, α-syn folds into a distinctive conformation that has not been observed previously. Moreover, the heparin-α-syn complex fibrils exhibit diminished neuropathology in primary neurons. Our work provides the structural mechanism for how heparin determines the assembly of α-syn fibrils, and emphasizes the important role of biological polymers in the conformational selection and neuropathology regulation of amyloid fibrils.
α-Synuclein (α-syn) is a key pathogenic protein involved in Parkinson’s disease (PD) and other synucleinopathies\textsuperscript{1,2}. It is a small highly-charged protein mainly expressed in neurons and is involved in normal functions such as neurotransmission\textsuperscript{3}. α-Syn is innately unstructured and forms various conformations depending on the cellular context. It remains unfolded in the cytosol or forms an α-helix structure in association with cell membranes\textsuperscript{4,5}. Under pathological conditions, it undergoes polymerization via non-covalent inter-molecular interactions such as hydrogen bonding and π-π stacking, to form β-strand-rich amyloid fibrils\textsuperscript{6,7}. These fibrils are toxic to neurons, deposition of which in pathological inclusions is a pathological hallmark of synucleinopathies such as PD, multiple system atrophy (MSA) and dementia with Lewy bodies (DLB)\textsuperscript{8}.

Similar to prion proteins, α-syn has been indicated to form different conformational fibrils (strains) in different synucleinopathies\textsuperscript{9–14}, and the α-syn fibrils also spread in a prion-like manner in the brain\textsuperscript{15–17}. Consistently, high-resolution structural determination of α-syn fibrils has unveiled a variety of polymorphic structures of either in vitro fibrils or ex vivo fibrils extracted from the brain of patients\textsuperscript{7,18–23}. Notably, the ex vivo fibrils purified from patients with MSA exhibit modification on the amino-acid side chains via covalent posttranslational modifications (PTMs) as well as noncovalently bound with unidentified molecular ligands\textsuperscript{7}. Chemical modification has also been widely observed in Tau fibrils purified from patients with various tauopathies\textsuperscript{24,25}. Although the chemical modifications of the pathological fibrils have not been well identified yet, they are apparently highly associated with the formation and pathology of the pathological fibrils.

Glycosaminoglycans (GAGs) are integral components of the extracellular matrix, which is involved in the cellular uptake of amyloid fibril seeds during the spread of fibrils in the brain\textsuperscript{26–28}. GAGs have also been found in amyloid deposits such as Lewy bodies, and are known to influence amyloid aggregation\textsuperscript{29,30}. For example, heparin, a representative GAG, can stimulate the amyloid aggregation of α-syn in vitro\textsuperscript{31,32}, but inhibit fibril spreading by blocking the binding of fibril seeds with the cell surface\textsuperscript{26}. However, the molecular mechanism by which heparin influences α-syn fibril formation and pathology remains elusive.

In this work, we used cryo-EM to determine the atomic structures of α-syn fibrils that were formed in the presence of heparin and comparatively in the absence of heparin. The structures show that heparin not only presents as a component of the fibril core, but also leads to alternative assemblies of α-syn fibrils, in which a new fold of α-syn was determined. We further show that the heparin-α-syn complex fibrils are less pathological to primary neurons than the apo-fibrils (control fibrils that are formed without heparin). Our work provides mechanistic understanding for the impact of heparin on the structure and pathology of α-syn fibrils, and highlights the potential of biological polymers in the determination of fibril polymorphs.

**Results**

**Heparin alters the fibrillar assembly of α-syn.** To investigate how heparin influences α-syn fibrillation, we began with the thioflavin T (ThT) kinetic assay and morphological characterization by negative staining transmission electron microscopy (TEM). The results showed that heparin significantly promotes α-syn fibrillation in a dose-dependent manner (Fig. 1a), which is consistent with previous reports\textsuperscript{33}. TEM imaging further showed that the fibrils formed in the presence of heparin (referred to as hep-α-syn fibrils) are morphologically distinct from those formed in the absence of heparin (referred to as apo-α-syn fibrils) (Fig. 1b).

To further gain atomic details of the fibrils, we prepared cryo-EM samples of the hep-α-syn and apo-α-syn fibrils for structure determination. The cryo-EM micrographs were acquired at ×22,500 magnification on a 300 kV Titan Krios microscope equipped with the K3 Summit camera. 92,118 micrographs were used for the reconstruction of the hep-α-syn fibrils (Table 1). 38,830 micrographs from 2321 micrographs were picked for the apo-α-syn fibrils. 2D classification revealed that the hep-α-syn fibrils comprise four different polymorphs (referred to as Hep-P1, -P2, -P3, and -P4, respectively) (Fig. 1c). These polymorphs feature different helical parameters including fibril pitch, twist angle and helical rise (Table 1). Three of them including Hep-P1, P2, and P4 contain a single protofilament; in contrast, Hep-P3 is composed of two protofilaments (Fig. 1d). The conformation of α-syn monomer in Hep-P1, P2, and P3 fibrils appears similar, but the overall conformations of fibrils are different in helical parameters (Fig. 1d, Table 1). These hep-α-syn fibril polymorphs are largely distinct from the apo-α-syn fibril in terms of both the conformation of α-syn monomer and the helical parameters of the overall fibril (Fig. 1d, Table 1). The apo-α-syn fibril...
According to the density maps, we unambiguously built the structural models for Hep-P1 and Hep-P3. Hep-P2 is a monomer, and the resolution of its density map is lower than that of Hep-P1. We thus did not build a structural model for Hep-P2. Hep-P1 contains a single protaminal polymorph that replicates that of the α-syn fibril prepared under the same condition reported previously18 (Supplementary Fig. 1). Strikingly, additional densities are present surrounding or in the interface of the protofilaments of the heparin (Fig. 1d). These densities are isolated from the polypeptide chain into the structure models, indicating the incorporation of heparin into the fibril assembly. In addition, we confirmed that both heparin and apo-α-syn fibrils were formed by full-length α-syn by immunogold labeling TEM (Supplementary Fig. 2). Taken together, these observations indicate that heparin involves in the fibrillar assembly of α-syn, changes the fibril structure and generates multiple polymorphs.

### Structures of the Hep-α-syn fibril polymorphs P1, P2 and P3.

The overall resolutions of the cryo-EM density maps of Hep-P1 and P3 are 3.2 Å and 3.1 Å, respectively (Supplementary Fig. 3 and Table 1). According to the density maps, we unambiguously built the structural models for Hep-P1 and Hep-P3. Hep-P2 is highly similar to Hep-P1 in terms of the conformation of α-syn monomer, and the resolution of its density map is lower than that of Hep-P1. We thus did not build a structural model for Hep-P2. Hep-P1 contains a single protofilament and features a left-handed helix with a half pitch of 64.4 nm (Fig. 2a, Supplementary Fig. 3). Notably, there are two additional densities observed in adjacent to the positively charged surfaces extended along the fibril axis: one is formed by Lys43 and Lys45, and the other is formed by Lys58, Lys60 and K97 (Supplementary Fig. 4, Fig. 2b, c), which indicates the negatively charged heparin may accommodate in these two positions.

We next performed molecular docking of heparin molecules into the two densities along the fibril axis. The heparin molecules can be well fitted into the density (Fig. 2d). On the Lys43-Lys45 surface (site I), the sulfonic acid group of heparin forms a salt bridge with Lys43 of α-syn. The distance between sulfonic acid groups of heparins and the side chains of Lys43 range from 3.70 to 4.23 Å along the fibril axis. In the Lys58-Lys60-Lys97 binding surface (site II), the sulfonic acid groups of heparin forms salt bridges with Lys58, Lys60, and Lys97 of α-syn (Fig. 2d). Note that the envelopes of the extra densities appear to be larger than the size of the heparin molecules from docking, which suggests that there may be alternative conformations of binding.

The overall architecture of the Hep-P1 fibril core is similar to that of the protofilament in polymorphs 2a and 2b reported previously20 (Supplementary Fig. 5A). However, in polymorph 2a or 2b, instead of being stabilized by heparin, Lys43 forms a salt bridge with Glu57 (polymorph 2a) or Glu46 (polymorph 2b) of the neighbouring subunit leading to the pairing of two intertwining protofilaments. Thus, heparin blocks the interaction between Lys45 and Glu57/Glu46 so as to maintain a single protofilamental polymorph of Hep-P1 (Fig. 2d, Supplementary Fig. 5B).

---

**Table 1 Statistics of cryo-EM data collection, refinement and validation.**

| Name          | Hep-P1 | Hep-P2 | Hep-P3 | Hep-P4 | Apo-α-syn fibrils
|---------------|--------|--------|--------|--------|-------------------|
| PDB ID        | 7V4A   | -      | 7V4B   | 7V4C   | -                |
| EMDB ID       | EMD-31705 | -    | EMD-31706   | EMD-31707   | - |
| Data Collection |        |        |        |        |                  |
| Pixel size (Å) | 1.06   | 1.06   | 1.06   | 1.06   | 1.06             |
| Defocus Range (μm) | -2.0 to -1.0 | -2.0 to -1.0 | -2.0 to -1.0 | -2.0 to -1.0 | -2.0 to -1.0 |
| Voltage (kV)  | 300    | 300    | 300    | 300    | 300              |
| Camera        | K3     | K3     | K3     | K3     | K3               |
| Microscope    | Titan Krios | Titan Krios | Titan Krios | Titan Krios | Titan Krios |
| Exposure time (s/frame) | 0.097 | 0.097 | 0.097 | 0.097 | 0.097 |
| Number of frames | 32   | 32     | 32     | 32     | 32               |
| Total dose (e/Å²) | 5573  | 5473   | 5473   | 5473   | 38,830           |
| Reconstructions |        |        |        |        |                  |
| Micrographs   | 5473   | 5473   | 5473   | 5473   | 38,830           |
| Manually picked fibrils | 92,118 | 92,118 | 92,118 | 92,118 | 38,830 |
| Box size (pixel) | 610   | 686    | 686    | 686    | 686              |
| Inter-box distance (Å) | 64.66 | 72.72  | 42.19  | 17.60  | 30.53            |
| Segments extracted | 83,529 | 291,650 | 262,084 | 188,227 | 583,394 |
| Segments after Class2D | 60,383 | 157,139 | 139,930 | 184,245 | 227,177 |
| Segments after Class3D | 20,111 | 94,743  | 47,063  | 38,286  | 105,423          |
| Resolution (Å) | 3.2    | -      | 3.1    | 3.4    | 3.5              |
| Map sharpening B-factor (Å²) | -95.39 | -      | -100.97 | -105.77 | -105.77 |
| Half pitch (nm) | 64.3  | 140.2  | 161.2  | 28.2   | 128.1            |
| Helical rise (Å) | 4.83  | 4.80   | 4.24   | 4.80   | 4.24             |
| Helical twist (°) | -1.35 | -0.62  | 179.73 | -3.06  | 179.66           |
| Atomic model   |        |        |        |        |                  |
| Non-hydrogen atoms | 1653   | -      | 3336   | 1287   | -                |
| Protein residues | 240   | -      | 480    | 186    | -                |
| Ligands        | 0      | -      | 0      | 0      | -                |
| r.m.s.d. Bond lengths | 0.002 | -      | 0.006  | 0.008  | -                |
| r.m.s.d. Bond angles | 0.518 | -      | 0.597  | 0.745  | -                |
| All-atom clash score | 8.54  | -      | 15.32  | 11.74  | -                |
| Rotamer outliers | 0.00% | -      | 0.00%  | 0.00%  | -                |
| Ramachandran Outliers | 0.00% | -      | 0.00%  | 0.00%  | -                |
| Ramachandran Allowed | 7.89% | -      | 13.16% | 20.00% | -                |
| Ramachandran Favored | 92.11%| -      | 86.84% | 80.00% | -                |

* Same structure as a previously reported α-syn fibril structure (PDB ID: 6A6B)18 based on the density map.
A distinctive fold of α-syn in polymorph Hep-P4. The overall resolution of the cryo-EM density map of Hep-P4 is 3.4 Å (Fig. 4a, Supplementary Fig. 3, Table 1). According to the density maps, we built the structural model for Hep-P4. Hep-P4 contains a single protofilament with a half pitch of 28.2 nm (Fig. 4a), which is the shortest among all the α-syn fibril structures reported so far.2,18,23,33–42 The fibril core of Hep-P4 is composed of residues 37–98 which arranges into a “Z” fold (Fig. 4a, b), which is distinctive from all known α-syn fibril structures reported so far. Three additional density blobs were identified close to the positively charged surface of the Hep-P4 fibril core (Fig. 4a–c, Supplementary Fig. 4), indicating heparin molecules involved in the Hep-P4 fibril formation. Molecular docking data revealed that heparin molecules bind to sites K43–K45 and K58–K60, similar to the heparin binding pattern in the Hep-P1 fibril (Fig. 2d). In contrast, K80 which is buried inside the fibril core of Hep-P1 is now exposed to the solvent and serves as a third heparin binding site (Fig. 4d and Supplementary Fig. 6). The binding of heparin with K80 blocks the wrap-over of the N-terminus leading to the open up of the V-shaped structural motif formed by residues 68–79 (Supplementary Fig. 6). Interestingly, the C-terminal half of Hep-P4 containing residues 73–98 forms a structural motif highly similar to that in the so-called type 3 polymorph determined from the fibrils seeded with the cerebrospinal fluid (CSF) of a postmortem patient with PD.42 (Supplementary Fig. 7A). Such a similar motif also shares some similarity with that in the in vitro polymorph 1a18, and ex vivo fibril polymorphs purified.

A cryo-EM structure of the Hep-P1 fibril. a Cryo-EM density map of the Hep-P1 fibril. The fibril parameters including the length of half pitch (180° helical turn), helical rise and twist angle are indicated. Extra densities for heparin are colored in red in the density map. No specified radius was used to plot around residues/heparin. b Cross-section view of the structural model fitted in the density map. The density map is the same map in (a) but restricted to areas within a 2 Å radius of the α-syn model, and then combined with the heparin densities in (a). c Cross-section view of the electrostatic potential surface of the Hep-P1 fibril. The heparin-binding sites are highlighted dash boxes. A surface potential color bar is shown. d Molecular docking of heparin into the extra densities. Heparin molecules are shown in sticks and colored in purple. Cross-section view is shown on the left. Side view is shown in boxes on the right.

A cryo-EM structure of the Hep-P3 fibril. a Cryo-EM density map of the Hep-P3 fibril. The fibril parameters including the length of half pitch (180° helical turn), helical rise and twist angle are indicated. The two protofilaments are colored in blue and purple, respectively. Extra densities are displayed with the same threshold (0.008) as protein densities. Extra densities for heparin are colored in orange in the density map. No specified radius was used to plot around residues/heparin. b Cross-section view of the structural model fitted in the density map. The density map is the same map in (a) but restricted to areas within a 2 Å radius of the α-syn model, and then combined with the heparin densities in (a). c Cross-section view of the electrostatic potential surface of the Hep-P3 fibril. The heparin-binding sites are highlighted dash boxes. A surface potential color bar is shown. d Molecular docking of heparin into the extra densities. Heparin molecules are shown in sticks and colored in purple. Cross-section view is shown on the left. Side view is shown in boxes on the right.
Significantly, PFFs and apo-α-syn to that in heparin-comparable sizes and amounts of apo- and heparin-induced by exogenous preformed bound polymorphs of α-syn.

Finally, we sought to examine the neuropathology of these heparin-aggregation of endogenous α-syn in vitro. We used an equal amount of apo- and heparin-α-syn PFFs (0.1% or 0.5%) to seed the aggregation of monomeric α-syn.

Remarkably, the result showed decreased seeding activity of the heparin-α-syn PFFs compared to the apo-α-syn PFFs, with a significantly elongated lag time of the seeded aggregation (Supplementary Fig. 10).

We next sought to further examine the seeding capacity of the PFFs in neurons. Given that the binding of heparin would block the cellular uptake of α-syn PFFs, to overcome this problem, we used liposomes to deliver PFFs into the cells (Supplementary Fig. 11A). We performed a gradient level of α-syn PFFs (5 nM, 20 nM, 80 nM, and 200 nM), and the result showed the induction of endogenous α-syn aggregation by PFFs in a dose-dependent manner (Supplementary Fig. 11B, C). More importantly, compared to the apo-α-syn PFFs, the heparin-α-syn PFFs exhibited a significantly weaker seeding activity in inducing aggregation of endogenous α-syn in primary neurons (Supplementary Fig. 11B, C), which is consistent with the result of in vitro ThT assay (Supplementary Fig. 10).

Collectively, these results demonstrate that the heparin-α-syn complex fibrils are less pathogenic than the apo fibrils in the aspects of neuronal binding and uptake, as well as the seeding activity, which indicates that ligand binding can not only alter the structure but also the pathology of amyloid fibrils.

**Discussion**

Structural polymorphism is a unique property of amyloid fibrils, which underlies the pathological heterogeneity of neurodegenerative diseases. Recent structural studies have revealed several polymorphic fibril structures formed by α-syn under different conditions. However, what determines the conformation of α-syn fibrils remains elusive. Cryo-EM structures of α-syn fibrils purified from the brain of patients with MSA unveiled the involvement of chemical modifications including covalent PTM and unidentified non-covalent cofactor binding in the fibril assembly. Similar modifications have also been found in Tau fibrils purified from human tissues. These evidences indicate the important role of non-proteinaceous components in the conformational selection of amyloid fibrils. Notably, the ex vivo α-syn fibrils of MSA contain negatively charged molecules which play an essential role in mediating the interface between protofilaments. Unfortunately, these molecules were not able to be identified. However, several negatively charged molecules, e.g., GAGs, indeed have been found to influence α-syn fibril formation. In this work, we showed that heparin, one of the most studied GAGs, can induce α-syn to form special fibril polymorphs by both blocking the original intra- and inter-molecular interactions and establishing new interactions (Fig. 5).

**Diminished neuropathology of heparin-α-syn complex fibrils.** Finally, we sought to examine the neuropathology of these heparin-bound polymorphs of α-syn fibrils. A well-established neuronal propagation assay was performed to monitor the pathological aggregation of endogenous α-syn in primary cortical neurons induced by exogenous preformed α-syn fibrils (PFFs). We applied comparable sizes and amounts of apo- and heparin-α-syn to the primary neurons (Supplementary Fig. 8), as well as a control sample of apo-α-syn PFFs supplemented with heparin in a comparable amount to that in heparin-α-syn PFFs in the medium. Strikingly, compared with the apo-α-syn PFFs, both the heparin-α-syn PFFs and apo-α-syn PFFs supplemented with heparin-induced significantly less pathological α-syn aggregation in neurons immunostained by pS129 α-syn antibody (Supplementary Fig. 9A), which is consistent with previous studies showing that heparin can inhibit the cellular uptake of α-syn fibrils.

To confirm the role heparin in the reduced capability of heparin-α-syn PFFs in inducing endogenous α-syn aggregation in neurons, we measured the neuronal surface binding and cellular uptake of the heparin-α-syn PFFs in comparison with the apo-α-syn PFFs. As shown in Supplementary Fig. 9B, the heparin-α-syn PFFs displayed a dramatically decreased ability of neuronal binding compared to the apo-α-syn PFFs. In addition, the neuronal uptake of heparin-α-syn PFFs also decreased compared to that of the apo-α-syn PFFs (Supplementary Fig. 9C).

Since the reduced capability of heparin-α-syn PFFs is attributed to heparin, it is still not known whether the apo- and heparin-α-syn PFFs have different activities in seeding endogenous α-syn, if the endogenous α-syn could be exposed to comparable amounts of these PFFs. Therefore, we performed the ThT kinetic assay in vitro. We used an equal amount of apo- and heparin-α-syn PFFs (0.1% or 0.5%) to seed the aggregation of monomeric α-syn.

Collectively, these results demonstrate that the heparin-α-syn complex fibrils are less pathogenic than the apo fibrils in the aspects of neuronal binding and uptake, as well as the seeding activity, which indicates that ligand binding can not only alter the structure but also the pathology of amyloid fibrils.

**Fig. 4 Cryo-EM structure of the Hep-P4 fibril.** a Cryo-EM density map of the Hep-P4 fibril. The fibril parameters including the length of half pitch (180° helical turn), helical rise and twist angle are indicated. Extra densities are displayed with the same threshold (0.0095) as protein densities. Extra densities for heparin are colored in orange in the density map. b Cross-section view of the structural model fitted in the density map. The density map is the same map in (a) but restricted to areas within a 2 Å radius of the α-syn model, and then combined with the heparin densities in (a). c Cross-section view of the electrostatic potential surface of the Hep-P1 fibril. The heparin-binding sites are highlighted dash boxes. A surface potential color bar is shown. d Molecular docking of heparin into the extra densities. Heparin molecules are shown in sticks and colored in purple. Cross-section view is shown on the left. Side view is shown in boxes on the right.

from patients with MSA (Supplementary Fig. 7A). In contrast, the N-terminal half of Hep-P4 containing residues 37–72 forms a structural motif nearly identical to that in Hep-P1, as well as that in polymorphs 2a and 2b (Supplementary Fig. 7B). Thus, Hep-P4 appears as a hybrid of two common structural motifs seen in the known α-syn fibril structures.
Fig. 5 Schematic diagram of the polymorphism of α-syn fibrils induced by heparin. a Charge interactions of heparin with lysine residues that are buried inside the polyomorphs 2a/2b fold block α-syn fibrils into polyomorphs 2a/2b. Instead, α-syn forms a distinctive fold in complex with heparin. b Heparin disrupts the charge interactions between the protofilaments, which results in polyomorphs either containing a single protofilament, or forming an interface mediated by heparin.

Of note, we do not think that these in vitro fibrils could fully replicate the native conformations of α-syn fibrils due to the lack of native modifications. Scheres and colleagues have recently reported that heparin induced Tau to form polymorphic filaments that differ from those in Alzheimer’s and Pick’s diseases. Nevertheless, our work reveals how α-syn polymorphic fibrils could be regulated by noncovalent ligand binding, which not only provides fundamental understanding for the regulation of ligands to the polymorphism of amyloid fibrils, but also provides a strategy to intervene in fibril pathology.

Diamond and colleagues found that heparan sulfate proteoglycans (HSPGs) play an important role in mediating cellular uptake of α-syn and Tau, which can be blocked by the addition of heparin. Consistently, our primary neuron assay showed that the heparin-α-syn complex fibrils exhibit largely attenuated neuropathology (Supplementary Fig. 9). These phenomena can be well explained by the structures of the heparin-α-syn complex fibrils, in which heparin shields available binding sites for HSPGs by either directly binding with lysine residues (K43, K45, K58, K60 and K80) of α-syn, or rearranging the fibril structures. Note that heparin may not only bind with the lysine residues in the fibril core; those N-terminal of the fibril core may also interact with heparin via charged interactions. As a result, HSPGs are not able to well recognize heparin-α-syn fibrils for cell uptake. Of note, in addition to HSPGs, cell surface protein receptors including LAG3 and APLP1 were also found to directly bind with α-syn fibrils. However, their mechanisms differ from that of HSPGs. LAG3 and APLP1 recognize the negatively charged C-terminal region of α-syn rather than the lysine residues on the fibril spines. This is consistent with our observation that heparin-α-syn fibrils still maintain some degree of membrane binding and neuronal propagation abilities. Nevertheless, development of heparin-like molecules to efficiently shield the lysine residues on the fibril interface of α-syn may provide a promising strategy for the inhibitor design to prevent the spread of pathological α-syn fibrils. Our structural study may inform rational design of such inhibitors.

Methods

Recombinant α-syn monomer expression and purification. The N-terminally acetylated human wild type (WT) α-syn monomer was over-expressed and purified from E. coli BL21 (DE3) cells. The gene encoding human full-length WT α-syn was inserted into pET-22b (+) vector and co-transformed with fusion yeast N-acetyltransferase complex B in pACYC-Duet-1 vector. E. coli BL21 (DE3) cells bearing the two plasmids were treated with 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG) at 25 °C for 12 h to induce protein expression. Cells were collected, resuspended in 100 mM Tris-HCl (pH 8.0), 1 mM EDTA, with 1 mM phenylmethylsulfonyl fluoride (PMSF), and lysed through high-pressure cell crusher. After centrifugation at 20,817 × g for 30 min, the supernatant was collected and boiled for 10 min. After centrifugation, 20 mg ml \(^{-1}\) streptomycin was added in the supernatant to remove nucleic acids. After a second round of centrifugation, the pH of supernatant was adjusted to 3.5 with 2 M HCl to precipitate other proteins. Then the supernatant was dialyzed in 25 mM Tris-HCl (pH 8.0) at 4 °C overnight. After dialysis, the protein sample was purified sequentially by Q column (GE Healthcare, 17-5156-01) and Superdex 75 column (GE Healthcare, 28-9893-33). For Superdex 75 column, the target protein was eluted with the buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM KCl. The concentration of purified α-syn monomer was determined by Pierce bicinchoninic acid (BCA) protein assay kit (ThermoFisher Scientific, 23227). The purity of protein sample was verified by SDS-PAGE.

ThT kinetic assay. The reaction mixture contained 50 μM α-syn monomer, 50 μM THT, 0.05% Na2S, in 50 mM Tris-HCl (pH 7.5), 150 mM KCl, in the presence of 0–600 μM heparin (Sigma-Aldrich, H3149) as indicated. Reactions were performed in a black 384-well plate with a clear bottom (ThermoFisher Scientific, 142761). The plate was continuously shaken (900 rpm, orbital) at 37 °C in the BMG FLUOSTar Omega plate reader. The fluorescent intensities of each reaction were recorded at excitation of 440 nm and emission of 480 nm every 2 h. The kinetic curves were graphed with GraphPad Prism 8.

Preparation of apo-α-syn fibrils and hep-α-syn fibrils. Recombinant α-syn monomer (200 μM) in buffer containing 50 mM Tris-HCl, 150 mM KCl, 0.05% Na2S, pH 7.5) was continuously shaken at 900 rpm in the absence (for apo-α-syn fibrils) or presence (for hep-α-syn fibrils) of 2.4 mg ml \(^{-1}\) heparin in ThermoMixer (Eppendorf). After 5 days agitation, the α-syn fibril samples were sonicated on ice for 30 s (1 s on, 1 s off, 20% amplitude, J92-IIIN sonicator) to obtain seeds. For cryo-EM, negative-staining transmission electron microscopy (TEM), and primary cortical neuronal experiments, α-syn monomer (50 μM, in buffer containing 50 mM Tris-HCl, 150 mM KCl, 0.05% Na2S, pH 7.5) was incubated with 1% (molar ratio) preformed fibril seeds in the absence (for apo-α-syn fibrils) or presence (for hep-α-syn fibrils) of 600 μM heparin with 900 rpm agitation for 5 days. The morphologies of mature apo-α-syn fibrils and hep-α-syn fibrils were validated by negative-staining TEM.

Negative-staining TEM. A drop of 5 μl fibril samples were loaded onto the glow-discharged 200 mesh carbon support film copper grids (Beijing Zhongjingkeyi Technology Co., Ltd.). After incubations of 45 s, the grids were washed with 5 μl double-distilled water followed by 3% uranyl acetate, then, the grids were stained with 3% uranyl acetate for another 45 s. Finally, the grids were dried in air and applied to a Tecnai T12 microscope (FEI Company) operated at 120 kV for negative staining TEM imaging.

Immunogold labeling. 200 mesh carbon support film copper grids (Beijing Zhongjingkeyi Technology Co., Ltd.) were glow-discharged for 45 s before sample preparation. 5 μl of 10 μM fibril sample solutions were applied to the grids and incubated for 2 min, then excess sample solution were blotted off using the filter paper. Then, blocking buffer containing 0.1% (w/v) BSA in PBS, pH 7.4 was applied to the grids and incubated for 10 min, excess solution was blotted off. Primary antibodies specific for N-terminus (Syn303, Cat.# MMS-5085, BioLegend, mouse monoclonal IgG, epitope residues 1–5) or C-terminus of α-syn (Cat.# ab138501, abcam, rabbit monoclonal IgG, epitope residues 118–123) diluted 1:100 in blocking buffer was applied to the grids and incubated for 2 h, excess solution was blotted off. Control grids were applied in the absence of α-syn antibodies. The grids were washed once with PBS, and excess liquid was blotted off. After that, 12 nm Colloidal Gold-AffiniPure Donkey Anti-Mouse IgG (Jackson Immunoresearch Laboratories, Inc., Catalog No. N-214-195-100) or 12 nm Colloidal Gold-AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., Catalog No. 711-205-125) diluted 1:50 in blocking buffer was applied to the grids and incubated for 1 h, excess solution was blotted off. The grids were washed once with PBS, and excess liquid was blotted off. The grids were negatively stained with 3% uranyl acetate for another 45 s. Finally, the grids were dried in air and applied to a Tecnai T12 microscope (FEI Company) operated at 120 kV for negative staining TEM imaging.

Cryo-EM data collection. Apo-α-syn fibrils and hep-α-syn fibrils at the concentration of 3 μM (4 μl) were applied to the glow-discharged holey carbon Cu grids (Quantifoil R2/1, 300 mesh) twice and then plunge-frozen in liquid ethane after blotted with filter paper. Cryo-EM data were acquired on a Titan Krios transmission electron microscope (FEI Company) operated at 300 kV with a Gatan K3 direct detector in super-resolution mode (3.00 Å). A total of 9,207,574 micrographs were acquired using a Titan Krios transmission electron microscope (FEI Company) operated at 300 kV with a Gatan K3 direct detector in super-resolution mode (3.00 Å).
resolution mode. 32 frame movies per micrograph were recorded at 22,500 magnification with a pixel size 1.06 Å pixel$^{-1}$. The total dose was $-55$ eÅ$^{-2}$ for a total exposure time of 3.11 s. For defocus values, a range of $-1.0$ to $-2.0$ µm was adopted. Automated cryo-EM data collection was performed by Serial EM 3.7-3 software.$^{25}$

**Image pre-processing, helical reconstruction and model building.** For image pre-processing, 32 movie frames per micrograph were corrected for beam induced motion, aligned, dose-weighted, and further binned with a physical pixel size of 1.06 Å using MotionCorr 1.2.1.$^{135}$ The resulting micrographs were used to estimate the contrast transfer function using CTFIND-4.1.$^{86}$ Fibrils were manually picked using the “Manual picking” program in RELION 3.1.$^{157}$ All subsequent helical reconstruction steps were performed in RELION 3.1.$^{157}$

**Hep-α-syn fibrils datasets.** 92,118 manually picked fibrils from 5473 micrographs were extracted to segments with a box size of 1200 pixels and an inter-box distance of 127.2 Å. Then, initial reference-free 2D classification steps with a decreasing in-plane angular sampling rate from 12° to 1° and a T = 2 regularization parameter were performed for four polymorphs. The optimized density maps were used for further 3D classifications (k = 1) for each polymorph. Helical symmetry local optimization of helical twist and rise after reconstructions was carried out. The helical parameters and initial 3D models that were low-pass-filtered to 60 Å were further applied to perform 3D classifications (k = 1) for each polymorph. Helical symmetry local optimization of helical twist and rise was performed while β-standards perpendicular to the helical axis were clearly separated. The optimized density maps were used for further 3D classifications (k = 3 followed by k = 1). 3D auto-refinements with optimization of helical twist and rise after reconstructions were carried out. The final helical rise of Hep-P1, Hep-P2, Hep-P3, and Hep-P4 were optimized to 4.83 Å, 4.80 Å, 2.42 Å, and 4.80 Å, respectively. The final helical twist of Hep-P1, Hep-P2, Hep-P3, and Hep-P4 were optimized to $-1.35°$, $-0.62°$, 179.73°, and $-3.06°$, respectively. For Hep-P1, Hep-P3, and Hep-P4, the maps were further sharpened using a standard post-processing program in RELION 3.1.$^{157}$ Overall resolution estimates were calculated based on the gold-standard 0.143 Fourier shell correlation (FSC) between the two independently refined half-maps. Reported overall resolution was 3.2 Å for Hep-P1, 3.1 Å for Hep-P3, and 3.4 Å for Hep-P4, respectively. Local resolution was estimated using the "Local resolution" procedure in RELION 3.1 with the same mask and β-factor in post-processing. Density maps are exhibited via UCSF Chimera 1.13.1.$^{8}$ The atomic models were built into the central region of the sharpened density map of α-synuclein in COOT 0.8.9.$^{2}$ A 3-layer models were generated and refined in the real-space refinement program in PHENIX 1.13.$^{157}$ Additional details for helical reconstruction and model building are given in Table 1.

**Neuronal propagation assay.** Primary cortical neurons cultured at 10 days (DIV10) were treated with PBS, 200 nM α-syn monomer, 200 nM apo-α-syn PFFs, 200 nM heparin-α-syn PFFs, and 200 nM apo-α-syn PFFs + 2.4 µg ml$^{-1}$ heparin (comparable amount of heparin with that in heparin-α-syn PFFs, mixed in medium) for 3 h. The entire sample was collected and fixed using immunostaining. Primary antibodies composition: anti-α-syn (Abcam, Cat.# ab51253, 1:1,000 dilution) and anti-α-syn PFFs (Abcam, Cat.# ab5392, 1:250 dilution). Secondary antibodies composition: Alexa Fluor 488-conjugated goat anti-rabbit (ThermoFisher Scientific, Cat.# A11039, 1:1,000 dilution) and Alexa Fluor 568-conjugated goat anti-chicken (ThermoFisher Scientific, Cat.# A11033, 1:1,000 dilution). The fluorescent images were scanned on a SP8 confocal microscope. The fluorescent gray values of α-syn and MAP2 signal were measured by ImageJ 2.0.0.

**Neuronal surface binding assay.** Following the previously established neuronal surface binding assay$^{69}$, primary cortical neurons cultured at 12 days (DIV12) were treated with PBS, 200 nM α-syn monomer, 200 nM apo-α-syn PFFs, and 200 nM heparin-α-syn PFFs for 2 h at 25 °C (3 biological replicates in each group), respectively. Then, the neurons were collected, washed, and fixed for immunostaining. Primary antibodies composition: anti-α-syn (Abcam, Cat.# ab138501, 1:1,000 dilution) and anti-α-syn PFFs (Abcam, Cat.# ab5392, 1:250 dilution). Secondary antibodies composition: Alexa Fluor 488-conjugated goat anti-chicken (ThermoFisher Scientific, Cat.# A11039, 1:1,000 dilution) and Alexa Fluor 568-conjugated goat anti-rabbit (ThermoFisher Scientific, Cat.# A11036, 1:1,000 dilution). The fluorescent images were scanned on a SP8 confocal microscope. The fluorescent gray values of α-syn and MAP2 signal were measured by ImageJ 2.0.0.

**Neuronal uptake assay.** Primary cortical neurons cultured at 12 days (DIV12) were treated with PBS, 400 nM α-syn monomer, 400 nM apo-α-syn PFFs, and 400 nM heparin-α-syn PFFs for 3 h at 37 °C (3 biological replicates in each group), respectively. Then neurons were washed three times with PBS and precipitated with 10% trichloroacetic acid (w/v) in PBS. The resulting pellets were washed twice with 10% trichloroacetic acid and dried. The pellets were dissolved in 37% dimethyl sulfoxide (DMSO) and normalized to the expression level of β-actin (Cell Signaling Technology, Cat.# 3700 S, 1:1000 dilution). The fluorescent images were scanned on a SP8 confocal microscope. The fluorescent gray values of α-syn and MAP2 signal were measured by ImageJ 2.0.0.

**Seeding amplification assay.** To compare the seeding property of the comparable amount of apo-α-syn PFFs and heparin-α-syn PFFs by ThT kinetic assay. Non-linear regression was used to fit each kinetic curves to a sigmoidal four parameters dose-response (variable slope) model implemented in GraphPad Prism. Briefly, equal volumes of Lipofuscinamine-2000 (Invitrogen) and α-syn PFFs solutions, both diluted in Neurobasal Medium (Thermo Fisher) without B27 supplement and Penicillin-Streptomycin, were combined to

**Liposome mediated seeds transduction.** To test the seeding potential of apo-α-syn PFFs and heparin-α-syn PFFs to endogenous α-syn, a previously published protocol was adopted.$^{182}$ Liposome mediated seeds transduction protocol was performed by Lipofectamine-2000 (Invitrogen) and α-syn PFFs solutions, both diluted in Neurobasal Medium (Thermo Fisher) without B27 supplement and Penicillin-Streptomycin, were combined to
give final concentrations of 0.4% (v/v) Lipofectamine-2000 and 5, 20, 80, 200 nM total α-syn, respectively, and then incubated for 20 min to allow liposome formation. Transduction mixture (100 μL per well) was added to primary cortical neurons plated in the 24-well plates that pre-covered with poly-D-lysine coated coverslips (150,000 cells/coverslip). After incubating for 24 h, the transduction medium was then removed and replaced with fresh Neurobasal Medium (Thermo Fisher) for an additional 7 days.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

Density maps of the Hep-P1, Hep-P3, and Hep-P4 fibrils have been deposited in the Electron Microscopy Data Bank (EMDB) under the accession codes EMD-31705 (Hep-P1), EMD-31706 (Hep-P3), and EMD-31707 (Hep-P4), respectively. The structural models have been deposited in the Protein Data Bank (PDB) under the accession codes 7VA4 (Hep-P1), 7VA4B (Hep-P3), and 7VA4C (Hep-P4), respectively. The structural models used in this study are available in the PDB database under accession codes 6AB (polymorph 1a), 6SSX (polymorph 2a), 6SS (polymorph 2b), and 6YXO (MSA PA-1). 7VA4 (CSF seeded type 3 polymorph) respectively. Other data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

Received: 21 December 2021; Accepted: 1 July 2022; Published online: 22 July 2022

**References**

1. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
2. Goedert, M., Jakes, R., Crowther, R. A. & Spillantini, M. G. in Parkinson’s Disease 33–59 (Springer, 2001).
3. Burre, J. et al. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667 (2010).
4. Theillet, F.-X. et al. Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature 530, 45–50 (2016).
5. Georgieva, E. R., Ramlall, T. F., Borbat, P. P., Freed, J. H. & Eliezer, D. 428, 323–328 (2004).
6. Collinge, J. & Clarke, A. R. A general model of prion strains and their pathogenicity. Science 318, 930–937 (2007).
7. Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
8. Kordower, J. H., Chiu, Y., Hauser, R. A., Freeman, T. B. & Olano, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506 (2008).
9. Breake, H. et al. Stage of brain pathology related to sporadic Parkinson’s disease. Neurobiol. aging 24, 197–211 (2003).
10. Li, Y. et al. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy. Cell Res. 28, 897–903 (2018).
11. Boyer, D. R. et al. Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nat. Struct. Mol. Biol. 26, 1044–1052 (2019).
12. Guerrero-Ferreira, R. et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. Elife 8, e45007 (2019).
13. Boyer, D. R. et al. The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Proc. Natl. Acad. Sci. 117, 3592–3602 (2020).
14. Sun, Y. et al. Cryo-EM structure of full-length α-synuclein amyloid fibril with Parkinson’s disease familial A53T mutation. Cell Res. 30, 360–362 (2020).
15. Sun, Y. et al. The hereditary mutation G51D unlocks a distinct fibril structure transmissible to wild-type α-synuclein. Nat. Commun. 12, 1–10 (2021).
16. Arakhamia, T. et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180, 633–644, e612 (2020).
17. Li, D. & Liu, C. Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease. Nat. Chem. Biol. 17, 237–245 (2021).
18. Holmes, B. B. et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. 110, E3138–E3147 (2013).
19. Soares da Costa, D., Reis, R. L. & Pashkuleva, I. Sulfation of glycosaminoglycans and its implications in human health and disorders. Annu. Rev. Biomed. Eng. 19, 1–26 (2017).
20. Zhang, Q. et al. A myosin-7B-dependent endocytosis pathway mediates cellular entry of α-synuclein fibrils and polycation-bearing cargos. Proc. Natl. Acad. Sci. 117, 10865–10875 (2020).
21. Perry, G. et al. Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res. 579, 350–352 (1992).
22. Dewitt, D. A., Richey, P., Praprotnik, D., Silver, J. & Perry, G. Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases. Brain Res. 656, 205–209 (1994).
23. Kohlbarg, J. A., Li, J., Uversky, V. N. & Fink, A. L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41, 1502–1511 (2002).
24. Mehra, S. et al. Glycosaminoglycans have variable effects on α-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils. J. Biol. Chem. 293, 12973–12991 (2018).
25. Guerrero-Ferreira, R. et al. Cryo-EM structure of alpha-synuclein fibrils. Elife 7, e36402 (2018).
26. Sawaya, M. R., Hughes, M. P., Rodrigue, J. A., Riek, R. & Eisenberg, D. S. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell 184, 4857–4873 (2021).
27. Li, B. et al. Cryo-EM of full-length α-synuclein reveals fibril morphologies with a common structural kernel. Nat. Commun. 9, 1–10 (2018).
28. Zhao, K. et al. Parkinson’s disease associated mutation E46K of α-synuclein triggers the formation of a distinct fibril structure. Nat. Commun. 11, 1–9 (2020).
29. Zhao, K. et al. Parkinson’s disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM. Proc. Natl. Acad. Sci. 117, 20305–20315 (2020).
30. McGlinchey, R. P., Ni, X., Shadish, J. A., Jiang, J. & Lee, J. C. The N terminus of α-synuclein dictates fibril formation. Proc. Natl. Acad. Sci. 118, e203487118 (2021).
31. Lövestam, S. et al. Seeded assembly in vitro does not replicate the structures of α-synuclein fibrils from multiple system atrophy. FEBS Open Bio. 11, 2599–1013 (2021).
32. Burger, D., Fenyi, A., Bousset, L., Stahlberg, H. & Melki, R. Cryo-EM structure of alpha-synuclein fibrils amplified by PMCA from PD and MSA patient brains. bioRxiv. https://doi.org/10.1101/2021.07.08.451731 (2021).
33. Fan, Y. et al. Different structures and pathologies of α-synuclein fibrils derived from preclinical and postmortem patients of Parkinson’s disease. bioRxiv. https://doi.org/10.1101/2021.02.467619 (2021).
34. Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein in Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135–2146 (2014).
35. Tycko, R. Amyloid polymorphism: structural basis and neurobiological relevance. Neuron 86, 632–645 (2015).
36. Jadanza, M. G., Jackson, M. P., Hewitt, E. W., Ransow, N. A. & Radford, S. E. A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol. 19, 755–773 (2018).
37. Scheres, S. H., Zhang, W., Falcon, B. & Goedert, M. Cryo-EM structures of tau filaments. Curr. Opin. Struct. Biol. 64, 17–25 (2020).
38. Shi, Y. et al. Structure-based Classification of Tauopathies. Nature 598, 359–363 (2021).
39. Zhang, W. et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. Elife 8, e43584 (2019).
49. Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, 621–625 (2016).
50. Zhang, S. et al. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson’s disease. Proc. Natl. Acad. Sci. 118, e2011196118 (2021).
51. Mao, X. et al. Aplp1 and the Aplp1–Lag3 Complex facilitates transmission of pathologic α-synuclein. bioRxiv. https://doi.org/10.1101/2021.05.01.442157 (2021).
52. Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36–51 (2005).
53. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. methods 14, 331–332 (2017).
54. Rohou, A. & Grigorieff, N. CTFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015).
55. Scheres, S. H. Amyloid structure determination in RELION-3.1. Acta Crystallogr. Sect. D: Struct. Biol. 76, 94–101 (2020).
56. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 486–501 (2010).
57. Adams, P. D. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 213–221 (2010).
58. Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Computational Chem. 30, 2785–2791 (2009).
59. Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Computational Chem. 31, 455–461 (2010).
60. Jurrus, E. et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 27, 112–128 (2018).
61. Lau, A. et al. α-Synuclein strains target distinct brain regions and cell types. Nat. Neurosci. 23, 21–31 (2020).
62. Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288 (2014).

Acknowledgements

We acknowledge Bo Sun and Xia Zhang in the School of Life Science and Technology, ShanghaiTech University for access to and support from the cryo-EM facilities. We would like to thank the Bio-Electron Microscopy Facility of ShanghaiTech University, and we are grateful to Qianqian Sun and Yaping Wang for their help in cryo-EM data collection. We thank the Cryo-Electron Microscopy center at Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry for help with TEM data collection. This work was supported by the National Natural Science Foundation (NSF) of China (82188101, 32171236 and 31872716 to C.L.; 32170683 to D.L.), the Fundamental Research Funds for the Central Universities (K20220228, to Y.W.) and the Information Technology Center and State Key Lab of Computer-Aided Design (CAD) & Computer Graphics (CG), Zhejiang University (to Y.W.).

Author contributions

Y.T., Y.S., D.L., and C.L. designed the project. Y.T., Y.S., and K.Z. prepared the apo-α-syn fibrils and hep-α-syn fibrils samples. Y.T., S.L., W.X., Q.X., and Q.Z. performed the biochemical assays. Y.T. and Y.S. prepared cryo-EM samples, and performed cryo-EM data collection, and processing. S.L., W.X., Q.X., and Q.Z. assisted in cryo-EM data collection and processing. Y.T., S.L., Q.X., and Q.Z. performed the neuronal assays. Y.W. performed the molecular docking for heparin. All the authors are involved in analyzing the data and contributed to manuscript discussion and editing. Y.T., D.L., and C.L. wrote the manuscript. Y.T., D.L., C.L., L.H., W.L., and Q.Z. revised the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-31790-7.

Correspondence and requests for materials should be addressed to Cong Liu or Dan Li.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022